Rheumatology drugs among the most costly on the PBS

Drugs for rheumatology conditions are among the highest growth items for the Pharmaceutical Benefits Scheme, a new report shows. In its expenditure summary for the last year, the PBS ranks tofacitinib, (Xeljanz), as the sixth highest drug in terms of growth in costs to the PBS. The oral  Janus kinase inhibitor for rheumatoid arthritis showed ...

Already a member?

Login to keep reading.

© 2021 the limbic